<DOC>
	<DOCNO>NCT00522067</DOCNO>
	<brief_summary>This phase II , open label , design seasonal study support annual strain update evaluating safety , clinical tolerability immunogenicity 2007-2008 formulation Novartis Vaccines ' adjuvanted , subunit influenza vaccine adult underlie chronic disease</brief_summary>
	<brief_title>Support Annual Strain Update , Safety Immunogenicity Inactivated , Adjuvanted Influenza Vaccine , Formulation 2007-2008 , When Administered Subjects 18-64 Years Affected Chronic Diseases .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 64 year age adult volunteer , mentally competent , willing able give write informed consent prior study entry , suffer least one chronic disease : hypertension , heart disease , chronic obstructive pulmonary disease ( COPD ) asthma , hepatic renal insufficiency , arteriosclerotic disease insulin dependent diabetes mellitus Hypersensitivity ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin neomycin sulphate component vaccine ; History neurological symptom sign , anaphylactic shock follow administration vaccine ; Known suspect impairment/ alteration immune function ; Having receive within past 12 month one injection influenza vaccine Any condition , opinion investigator , might interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
	<keyword>subunit influenza vaccine</keyword>
	<keyword>surface antigen</keyword>
</DOC>